NCT06922136View on ClinicalTrials.gov

Evaluation of the Performance and Safety of Hyalo Gyn® Gel Compared to Placebo in Postmenopausal Breast Cancer Survivors

NARecruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Vulvo Vaginal Atrophy
Interventions
DEVICE

Hyalo Gyn Vaginal Gel

Hyalo Gyn® is uniquely formulated with Hydeal-D®, a proprietary HA derivative component manufactured by Fidia Farmaceutici S.p.A.

OTHER

Placebo

Placebo

Trial Locations (6)

10128

RECRUITING

AO Ordine Mauriziano di Torino, Ospedale Umberto I, Torino

20141

RECRUITING

Istituto Europeo di Oncologia, Milan

27100

RECRUITING

Fondazione IRCCS Policlinico San Matteo, Pavia

40138

RECRUITING

Policlinico SantOrsola Malpighi, Bologna

50134

RECRUITING

AOUC Azienda Ospedaliero-Universitaria Careggi, Florence

00168

RECRUITING

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

Sponsors
All Listed Sponsors
lead

Fidia Farmaceutici s.p.a.

INDUSTRY